John Parkinson

The investigational antibody used to treat President Trump shows it reduced viral load and medical visits.

A new study shows disproportionate impact of the virus to this group.

These vital cells that are recovered from COVID-19 patients might be able to help people with compromised immune systems due to cancer therapy or transplantation.

While this trial for hospitalized COVID-19 patients has been discontinued, Lilly is continuing their other trials with the medication for COVID-19 treatment.

The company is planning to move forward after receiving a recommendation from the DSMB to start up the trial again.

A case study examines a treatment for a hospitalized case of the virus.

Investigators wanted to examine spontaneously reported adverse events and whether they were cause for concern.

Here is a look at the patterns within the variety of symptoms and presentations during physician exams.

A presenting author offers greater study insights into this novel therapy for the treatment of serious infections.

Its phase 3 COVE trial enrollment is complete and the company is working towards its goal of FDA approval.

A prospective study looked at the association of contract nursing and SARS-CoV-2 outbreaks.

Investigators wanted to look at real world experiences with combination therapy in older people living with HIV.

Results from the Pivotal ADAPT-PO study were reported.

Results show medication provides therapeutic response for Candida.

In a large nursing home study, asymptomatic and symptomatic residents were found to carry similar viral loads.

A study looked at weight gain when changing therapy regimens.

The participant was taking a placebo and the trial will continue according to initial reports.

Sulopenem was superior to ciprofloxacin for the treatment of uncomplicated urinary tract infections.

In a phase 1/2 randomized clinical trial, GlaxoSmithKline’s RSVPreF3 vaccine elicits a response.

Covaxx has developed its investigational vaccine and is currently in a phase 1/2 trial.

Data from a Phase 1/2 randomized controlled trial of vaccine candidate, BBIBP-CorV, is shown to be safe.

A letter signed by 80 researchers says the concept put forth by the Great Barrington Declaration is “a dangerous fallacy.”

Looking at certain characteristics in a blood test can help forecast patients’ course and inform clinicians’ determination on the course of treatment.

The company made the announcement Monday night.

The BioGX’s Xfree COVID-19 Direct RT-PCR test has the potential to increase testing capacity by millions per week.

New UK population study shows majority of those who test positive did not have typical symptoms associated with the virus.

Abbott’s IgM test offer high specificity and sensitivity 15 days after onset of symptoms.

Athersys has developed its MultiStem cell therapy for COVID-19 Acute respiratory distress syndrome (ARDS). Athersys CEO Gil Van Bokkelen, PhD, and CFO Ivor Macleod, recently spoke to Contagion providing background on the company and their MultiStem therapy.

RECOVERY trial reported hospitalized COVID-19 patients did not see a benefit compared to those patients who received usual care.